Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Inovio Pharmaceuticals, Inc. (INO : NSDQ)
 
 • Company Description   
Inovio Pharmaceuticals, Inc., formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The Company's electroporation DNA delivery technology uses brief, controlled electrical pulses to increase cellular DNA vaccine uptake. Inovio's clinical programs include human papillomavirus (HPV)/cervical cancer (therapeutic), avian influenza (preventative), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) vaccines. It is advancing preclinical research for a universal seasonal/pandemic influenza vaccine. The Company's partners and collaborators include University of Pennsylvania, National Microbiology Laboratory of the Public Health Agency of Canada, NIAID, Merck, ChronTech, University of Southampton, and HIV Vaccines Trial Network. Inovio Pharmaceuticals, Inc. is headquartered in Blue Bell, Pennsylvania.

Number of Employees: 134

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.33 Daily Weekly Monthly
20 Day Moving Average: 1,976,566 shares
Shares Outstanding: 36.67 (millions)
Market Capitalization: $48.78 (millions)
Beta: 1.31
52 Week High: $12.33
52 Week Low: $1.30
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -37.26% -40.66%
12 Week -15.82% -29.38%
Year To Date -27.32% -31.93%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
660 W. GERMANTOWN PIKE SUITE 110
-
PLYMOUTH MEETING,PA 19462
USA
ph: 267-440-4200
fax: 267-440-4242
investor.relations@inovio.com http://www.inovio.com
 
 • General Corporate Information   
Officers
Jacqueline E. Shea - Chief Executive Officer and President
Simon X. Benito - Chairman
Peter Kies - Chief Financial Officer
Roger D. Dansey - Director
Ann C. Miller - Director

Peer Information
Inovio Pharmaceuticals, Inc. (CORR.)
Inovio Pharmaceuticals, Inc. (RSPI)
Inovio Pharmaceuticals, Inc. (CGXP)
Inovio Pharmaceuticals, Inc. (BGEN)
Inovio Pharmaceuticals, Inc. (GTBP)
Inovio Pharmaceuticals, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 45773H409
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/14/25
Share - Related Items
Shares Outstanding: 36.67
Most Recent Split Date: 1.00 (0.08:1)
Beta: 1.31
Market Capitalization: $48.78 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.48 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.00 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/14/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.95
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 61.07%
vs. Previous Quarter: 26.09%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -44.44%
ROE
06/30/25 - -
03/31/25 - -136.93
12/31/24 - -132.12
ROA
06/30/25 - -
03/31/25 - -89.99
12/31/24 - -91.12
Current Ratio
06/30/25 - -
03/31/25 - 2.63
12/31/24 - 2.77
Quick Ratio
06/30/25 - -
03/31/25 - 2.63
12/31/24 - 2.77
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -34,091.52
12/31/24 - -49,199.08
Book Value
06/30/25 - -
03/31/25 - 1.40
12/31/24 - 1.90
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©